Core Insights - Halozyme Therapeutics, Inc. will host an Investor Conference Call on January 28, 2026, to discuss preliminary unaudited full year 2025 revenue results, updated financial guidance for 2026-2028, and a business update [1] Group 1: Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [3] - The company is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, impacting over one million patients through ten commercialized products across more than 100 global markets [3] - Halozyme has partnerships with leading pharmaceutical companies, including Roche, Takeda, Pfizer, and others, to utilize its drug delivery technology [3] Group 2: Product Development - Halozyme is developing Hypercon™, a microparticle technology aimed at enhancing drug concentration and reducing injection volume, which broadens the scope of therapeutics for subcutaneous delivery [4] - The company also focuses on drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [5] - Halozyme has two proprietary commercial products, Hylenex and XYOSTED, along with partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [5] Group 3: Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [6]

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as one of the top new stocks to buy in Ray Dalio's portfolio, with TD Cowen raising its price target from $79 to $90 while maintaining a Buy rating, indicating strong performance and positive outlook for the company [1] Group 1: Financial Performance and Projections - TD Cowen believes that forecasts regarding ongoing ENHANZE launches are overly conservative, suggesting that additional resources in late-stage development will likely enhance the momentum of the company's subcutaneous medication delivery technology [2] - The company is expected to improve its multi-year outlook following strong performance in recent quarters [1] Group 2: Strategic Partnerships - Halozyme Therapeutics has entered into a global collaboration and exclusive licensing agreement with Takeda for its ENHANZE drug delivery technology, which includes an upfront payment and potential future milestone payments from Takeda [3] - The agreement stipulates that Halozyme will receive royalties ranging from low to mid single digits on sales of products that include vedolizumab in conjunction with ENHANZE [3] Group 3: Company Overview - Halozyme Therapeutics is a biopharmaceutical technology platform company focused on developing, manufacturing, and commercializing drug-device combination products utilizing advanced auto-injector technology [4]

Core Viewpoint - Halozyme Therapeutics, Inc. has entered into a global collaboration and license agreement with Skye Bioscience, Inc. to develop and commercialize higher-dose, subcutaneous administration strategies for nimacimab, targeting the obesity market [1] Group 1: Agreement Details - Skye Bioscience has licensed Halozyme's ENHANZE drug delivery technology to expand its application in the obesity market [1] - Skye plans to evaluate multiple dose-ranging strategies for nimacimab, including combinations with GLP-1 receptor agonists [2] - The agreement includes milestone payments from Skye to Halozyme based on the achievement of specific development and commercialization events [2] Group 2: Financial Terms and Future Plans - Halozyme will receive mid-single digit royalties on net sales of nimacimab developed with ENHANZE for a minimum of 10 years [3] - Skye intends to initiate a Phase 2b clinical trial for nimacimab with ENHANZE in obesity by mid-2026 [3] - In pre-market trading, HALO shares are priced at $70.46, reflecting a 0.21% increase, while SKYE shares are at $0.97, showing an 11.44% increase [3]

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to improve patient experiences and outcomes for both emerging and established therapies [5] - The company is headquartered in San Diego, CA, with additional offices in Ewing, NJ; Minnetonka, MN; and Boston, MA [9] Leadership Appointment - Jim Lang has been elected to Halozyme's Board of Directors, bringing over 30 years of executive leadership experience in healthcare, life sciences, business services, and data analytics [1] - Dr. Helen Torley, president and CEO, expressed confidence in Mr. Lang's strategic insight and ability to drive growth, particularly through mergers and acquisitions [2] Previous Experience of Jim Lang - Mr. Lang previously served as CEO of EVERSANA, where he led the company’s growth through the acquisition of over twenty companies, culminating in a merger with Waltz Health in August 2025 [2] - He also transformed Decision Resources Group into a leading healthcare data and analytics firm through significant expansion and acquisitions [2] Current Board Positions - Mr. Lang serves on the board of Biovie, Inc., chairing both the Audit Committee and the Nominating and Corporate Governance Committee [3] - He is also on the board of OptimizeRx Corporation, acting as chair of the Compensation Committee [3] Strategic Vision - Mr. Lang expressed his honor in joining Halozyme's Board and highlighted the company's strong foundation and compelling growth strategy [4] - He aims to work with the leadership team to accelerate growth and enhance shareholder value [4] Product Innovations - Halozyme is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, improving patient convenience and reducing treatment burden [6] - The company is developing Hypercon™, an innovative microparticle technology expected to set a new standard in drug concentration, enhancing at-home and healthcare provider administration [7] - Halozyme also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [8]

Core Insights - Merus N.V. and Halozyme Therapeutics, Inc. have entered into a global non-exclusive collaboration and license agreement to develop and potentially commercialize the subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody [1][2][3] Company Overview - Halozyme is a biopharmaceutical company known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, aiming to improve patient experience and treatment efficiency [4][5] - Merus specializes in developing innovative full-length multispecific antibodies and antibody drug conjugates, referred to as Multiclonics, which have shown promising results in clinical studies [7][8] Collaboration Details - Under the agreement, Merus will make an upfront payment to Halozyme, along with potential future milestone payments based on commercial and sales achievements, if approved [3] - Halozyme is entitled to receive low to mid-single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term [3] Clinical Potential - Petosemtamab has shown encouraging results in clinical studies across various solid tumor cancers and is positioned to potentially become a first and best-in-class treatment for head and neck cancer and other indications [2][3]

Financial Performance - Royalty revenue increased 52% year-over-year to a record $236 million, driving total revenue to a record $354 million, representing a 22% increase year-over-year [1][3][13] - Net income rose 28% year-over-year to $175 million, with adjusted EBITDA increasing 35% year-over-year to $248 million [1][10][13] - GAAP diluted EPS increased 36% year-over-year to $1.43, while non-GAAP diluted EPS rose 35% year-over-year to $1.72 [1][10][13] Financial Guidance - The company raised its 2025 financial guidance ranges for total revenue to $1,300 - $1,375 million, representing year-over-year growth of 28% - 35% [1][11] - Adjusted EBITDA guidance was raised to $885 - $935 million, indicating year-over-year growth of 40% - 48% [1][11] - Non-GAAP diluted EPS guidance was increased to $6.10 - $6.50, reflecting year-over-year growth of 44% - 54% [1][11] Corporate Developments - The company announced a transition plan for its Chief Financial Officer, Nicole LaBrosse, who will remain in her position until a successor is found or until March 30, 2026 [2][5] - Halozyme is set to acquire Elektrofi, a biopharmaceutical company, for $750 million in upfront consideration, with additional milestone payments contingent upon product regulatory approvals [8][11] - The acquisition is expected to close in the fourth quarter of 2025, pending regulatory review [8][11] Product and Market Expansion - The company achieved two new indication approvals this quarter, enhancing its growth catalysts [3][4] - The continued success of ENHANZE-enabled therapies, including DARZALEX SC, Phesgo, and VYVGART Hytrulo, underscores the strength of Halozyme's royalty-driven business model [3][4] - The company anticipates revenue growth contributions from additional launched ENHANZE products to increase in 2026 and beyond [3][4]